A phase II study of sorafenib in malignant mesothelioma: results of CALGB 30307
- Citation:
- J Thorac Oncol vol 5 (10)
- Year:
- 2010
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 804
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA31946, CA33601, R01 CA135257, U10 CA031946, U10 CA033601
- Corr. Author:
- Authors:
- Sarita Dubey Pasi A. Jänne Lee Krug Herbert Pang Xiaofei Wang Robin Heinze Colleen Watt Jeff Crawford Robert Kratzke Everett Vokes Hedy Lee Kindler
- Networks:
- Study
- CALGB-30307
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- mesothelioma, sorafenib, vascular endothelial growth factor, tyrosine kinase inhibitor, clinical trial